Introduction {#S1}
============

Brain tumors of the childhood represent the leading cause of cancer-related deaths in children aged 0--14 years, and survivors often present long-term neurological sequelae that impair their quality of life ([@B95]). These cancer types include medulloblastoma (MB), which is the most common and most studied type of childhood brain tumor, ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs) ([@B39]). Pediatric brain cancers may originate from defects in embryonal development affecting cell types including neural stem cells (NSCs) and neuronal precursors, or dedifferentiation of mature neuronal or glial cells ([@B119]; [@B124]; [@B71]; [@B126]; [@B6]).

Normal development, cellular differentiation, and tissue specialization are finely regulated by various epigenetic mechanisms ([@B4]). Epigenetic regulation allows changes in chromatin structure that control gene expression without modifications in DNA sequence. Histone acetylation and DNA methylation feature among the most widely investigated epigenetic mechanisms ([@B117]). Histone acetyltransferases (HATs) and deacetylases (HDACs) play opposing roles in regulating gene expression. HATs transfer acetyl groups to the amino-terminal lysine residues of histones, thus increasing histone acetylation and transcriptional activity. On the other hand, HDACs remove acetyl groups, thus promoting chromatin condensation and overall repression of gene expression, in addition to displaying other, non-epigenetic actions ([@B60]; [@B107]; [@B20]; [@B82]). Changes in the expression and activity of HATs and HDACs were described in leukemias, and afterward in solid tumors, and in many cases decreased levels of histone acetylation were shown to correlate with clinical outcome. Therefore, HDAC inhibitors (HDACis) have become promising and widely investigated experimental anticancer agents ([@B63]; [@B70]).

Pediatric cancers hijack and modify biological processes involved in normal embryonic development, including epigenetic modifications, to promote tumor progression ([@B71]; [@B78]). An important component of childhood cancer biology is epigenetic reprogramming that can lock cells in a stem cell-like, poorly differentiated and highly proliferative phenotype ([@B64]). Accumulating evidence implicates epigenetic abnormalities in the genesis and progression of pediatric brain tumors. The relationship between epigenetic markers and patient survival has been investigated ([@B10]), and epigenetic modulators have shown promising effects in experimental models. Here we review the potential of HDACis in the treatment of selected types of brain cancer that afflict children.

Epigenetic Basis of Pediatric Brain Cancers {#S2}
===========================================

Mutations and genetic variations affecting epigenetic-regulating mechanisms are features of several types of childhood brain cancers, including MB, EPN, ATRT, and pediatric gliomas ([@B75]; [@B99]; [@B21]; [@B54]; [@B65]; [@B94]; [@B14]; [@B74]). In fact, MB and low-grade gliomas are among the types of pediatric tumors with highest frequency of mutation in genes encoding epigenetic regulators ([@B47]). MicroRNAs (miRNAs) regulate pediatric brain tumor cells at posttranscriptional/translational levels, acting on a range of functional aspects linked to cancer progression, including proliferation and stemness. The diagnostic, prognostic, and therapeutic potential of miRNAs has been increasingly highlighted ([@B31]; [@B67]; [@B102]). Epigenetic remodeling genes SMARCB1 and SMARCA4 are among the most frequently altered in pediatric brain tumors, with most cases of ATRT showing changes in those genes ([@B27]; [@B127]; [@B52]). Enhancer of zeste homolog 2 (EZH2), which is part of a Polycomb repressor complex that methylates lysine 27 of histone H3 (H3K27), leading to transcription inhibition, is often mutated or highly expressed in pediatric brain tumors ([@B47]; [@B68]; [@B58]; [@B23]; [@B134]).

A reduced histone acetylation state can contribute to cancer through repressing differentiation and tumor suppressor genes while allowing overexpression of genes promoting proliferation. Chromatin modifications mediated by histone acetylation can also epigenetically influence the tumor genetic landscape, for example by leading to DNA copy gain in the absence of chromosomal instability ([@B11]; [@B74]). HDACs play a central role in epigenetic regulation through reducing acetylation. It is currently known that some HDACs can either repress or activate gene transcription, in addition to displaying non-epigenetic activities by acting directly on nuclear and cytoplasmic proteins ([@B20]). For example, transcription factors E2F1, STAT1, STAT3, and NF-κB can be directly hyperacetylated by HDACis ([@B53]; [@B34]; [@B13]).

Histone acetyltransferases and deacetylases are currently classified into different classes. Class I HDACs include nuclear HDAC1, 2, 3, and 8. Class II HDACs occur in both the nucleus and cytoplasm and are classified into two subclasses: HDAC4, 5, 7, and 9 are grouped as IIa, whereas HDAC6 and 10 are classified as class IIb. Sirtuins constitute Class III HDACs, being found in the nucleus, cytoplasm, and mitochondria according to the specific type. Finally, HDAC11 has been proposed as a Class IV HDAC ([@B24]; [@B43]; [@B20]; [@B82]). Most deacetylase activity in mammalian cells has been attributed to Class I HDACs ([@B62]).

Increased HDAC2 expression ([@B98]), deletions or amplifications of histone methyltransferases and demethylases ([@B93]), DNA hypermethylation ([@B28]), and altered miRNA expression ([@B25]) have been reported in MB. High HDAC5 and HDAC9 expression is found in prognostically poor MB subgroups and significantly associated with poor overall survival, posing an independent risk factor ([@B85]). Other alterations in epigenetic components found in MB include truncating mutations in the KDM6A gene encoding a histone 3 lysine 27 demethylase ([@B54]), homozygous deletions of genes involved in histone lysine methylation, and amplification of the HAT gene MYST3 ([@B93]). Expression of HDAC2 is higher in patients with MB subgroups with poor prognosis (sonic hedgehog (SHH), Group 3 and Group 4), and *MYC*-amplified MB cell lines show increased mRNA levels of class I HDACs compared to the normal cerebellum ([@B22]).

Hypermethylation of the transcriptional repressor hypermethylated in cancer 1 (*H1C-1*) was identified in 83% of EPN samples ([@B125]). Global reduction of H3K27me3 analogous to H3K27M mutant gliomas, accompanied by CpGi hypermethylation, is found in EPN ([@B9]). Poor-prognosis EPNs show a CpG island methylator phenotype, where transcriptional silencing driven by CpG methylation converges on targets of the Polycomb repressive complex 2 (PRC2), which represses expression of differentiation genes through trimethylation of H3K27 ([@B76]). Posterior fossa type A (PFA) EPNs show low H3K27 methylation and high levels of Enhancer of Zeste Homologs Inhibitory Protein (*EZHIP*), which promotes a similar chromatin state compared to H3K27M ([@B51]). Enrichment of 5-carboxylcytosine (5caC) and increased *TET1* expression, which are involved in active DNA demethylation, are epigenetic hallmarks of EPN and SHH MB ([@B104]). Hypermethylated genes in EPN converge on defined sets of embryonic stem cell (ESC) targets, suggesting a linkage, mediated by epigenetic programming, between embryonic development and pediatric brain cancer ([@B111]; [@B74]).

Somatic mutations in the H3.3-ATRX-DAXX chromatin remodeling pathway and recurrent mutations in the gene encoding the histone 3 variant H3.3 are highly prevalent in pediatric glioblastoma ([@B108]). In diffuse intrinsic pontine glioma (DIPG), a deadly type of childhood glioblastoma, a mutation that leads to hypomethylation by replacing a lysine to methionine (K27M) on H3F3A and HIST1H3B/C genes encoding histone variants is the most frequent mutation ([@B131], [@B132]; [@B80]). Supporting the link between embryonic development and the arising of pediatric brain tumors, this histone mutation can contribute to resetting neural progenitors derived from human ESCs to a stem cell state, ultimately resulting in neoplastic transformation ([@B29]).

In ATRTs, HDAC1 is significantly differentially expressed ([@B116]), and the chromatin remodeling and tumor suppressor gene SMARCB1 represses Cyclin D1 transcription by recruiting the HDAC1 complex to its promoter, resulting in cell cycle arrest ([@B121]). A hallmark of malignant rhabdoid tumors is homozygous deletion or inactivation of SMARCB1. Histone acetylation and methylation patterns, as well as HDAC and HAT levels, are influenced by insulin-like growth factor receptor 1 (IGF-1R) signaling ([@B110]). For comprehensive reviews on the role of epigenetic changes as part of the biological basis of pediatric brain cancers, see [@B21] and [@B74].

Effects of HDAC Inhibition in Experimental Pediatric Brain Cancers {#S3}
==================================================================

Most HDACis widely used experimentally or clinically preferentially inhibit Class I and II HDACs. These agents include sodium butyrate (NaB), trichostatin A (TSA), valproic acid (VPA), suberoyl anilide hydroxamic acid (SAHA, vorinostat), panobinostat, belinostat, and romidepsin ([@B13]; [@B70]; [@B86]; [@B43]). HDACis induce anticancer effects in several experimental tumor types by targeting aberrant chromatin alterations, resulting in changes in cell proliferation, viability, differentiation, migration, and angiogenesis ([@B13]; [@B107]; [@B105]). In addition to modulating acetylation by inhibiting HDACs, HDACis may directly modulate miRNAs and also alter protein kinase signaling through acetylation-independent mechanisms ([@B16]; [@B5]). The HDACi TSA inhibits HDAC6, a predominantly cytoplasmic HDAC, which likely induces many effects independent of alterations in gene expression stimulated by histone acetylation ([@B53]; [@B16]; [@B34]). When combined with agents targeting other epigenetic regulators, such as EZH2, HDACis modulate acetylation and methylation of H3K27, through mechanisms involving PRC2 complex disruption ([@B73]). Below, we summarize studies examining the effects of HDACis in experimental models of pediatric brain tumors.

Medulloblastoma {#S3.SS1}
---------------

Medulloblastoma is currently classified within four distinct molecular subgroups, namely, WNT, SHH, Group 3, and Group 4, with subtypes within each group being now recognized ([@B72]). An early study by [@B48] showed that the HDACi MS-275 inhibits proliferation of Daoy and D283 Med MB cells. A subsequent study by Li and colleagues showed that VPA, which partially acts as a class I and II HDACi, when used at clinically safe concentrations, leads to growth inhibition, cell cycle arrest, apoptosis, senescence, differentiation, and inhibition of colony formation in Daoy and D283 Med cells. In addition, daily systemic injection of VPA (400 mg/kg) for 28 days significantly inhibits *in vivo* growth of Daoy and D283 Med xenografts in immunodeficient mice. These effects are associated with hyperacetylation of histone H3 and H4, activation of p21, and suppression of *TP53*, *CDK4*, and *c-MYC* ([@B69]). The HDACis SAHA, NaB, and TSA induce apoptotic cell death related to dissipation of mitochondrial membrane potential and activation of caspase-9 and -3 in Daoy and UW228-2 MB cells. These HDACis also enhance the cytotoxic effects of ionizing radiation in Daoy cells, and treatment with SAHA potentiates the cytotoxic actions of etoposide and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), but not vincristine ([@B113]). HDACi-induced TRAIL sensitization is associated with increased caspase-8 activation ([@B114]). VPA combined with interferon (IFN)-gamma restores caspase-8 expression and sensitivity to TRAIL in primary MB samples and significantly potentiates TRAIL-mediated suppression of MB growth *in vivo* ([@B40]). HDACi potentiation of ionizing radiation effects in MB cells was also reported by [@B61]. A variety of HDACis, including MS-275, SAHA, TSA, and VPA, are able to inhibit proliferation of MB cell lines and induce histone H4 hyperacetylation, reactivation of expression of growth regulatory genes, and induction of apoptosis, as well as reduction of MB xenograft growth *in vivo* ([@B30]). HDACis helminthosporium carbonum (HC)-toxin, SAHA, and panobinostat reduce viability and lead to radiosensitization accompanied by increased cell death in the HD-MB03 cell line, a preclinical model of Group 3 MB ([@B84]). Inhibition of class I HDACs in MB cells reduces metabolic activity, cell number, and viability and enhances sensitivity to HDACi specifically in *MYC*-amplified cells ([@B22]). Histone-mediated deregulation of expression of the Wnt antagonist Dickkopf-1 (DKK1) impairs its tumor-suppressing activity and contributes to experimental MB tumorigenesis, and treatment with TSA restores DKK1 in D283 Med cells ([@B123]). TSA significantly inhibits telomerase activity, increases expression of p53 and p21, and reduces cyclin-D levels in ONS-76 MB cells. Upregulation of Bax and cytochrome c correlates with pro-apoptotic effects in TSA-treated cells ([@B56]).

HDAC-mediated deacetylation of Gli (glioma-associated oncogene) promotes transcriptional activation through Hedgehog (Hh)-induced upregulation of HDAC1, and loss of HDAC activity hinders Hh pathway-dependent growth of neural progenitors and MB cells ([@B15]; [@B18]). The functional interaction between the transcription cofactor ZNF521 and GLI1 and GLI2, which enhances Hh signaling, is sensitive to HDACis ([@B109]). Hh signaling stimulates granule precursor (CGP) proliferation during the early stages of postnatal cerebellar development and sustains HDAC activation leading to stimulation of CGPs. HDAC inhibition impairs Shh-induced CGP proliferation and improves aberrant CGP proliferation in a mouse model of MB ([@B66]). NL-103, a dual-targeted inhibitor of both HDAC and Hh signaling, effectively overcame resistance to the Hh inhibitor vismodegib ([@B136]). HDAC6 is an important regulator of the Hh pathway, and selective HDAC6 inhibition hinders MB cell survival *in vitro* and reduces tumor growth in an *in vivo* allograft model ([@B19]). HDACis show more pronounced effects on proliferation of SHH-driven MB cells harboring a mutation in the gene encoding for the histone acetyltransferase (HAT) CREBBP, when compared to CREBBP wild-type controls ([@B44]). A targeted small-molecule screen on the stable, SHH-dependent murine MB cell line SMB21 reveals selective inhibitors of class I HDACs as promising antitumor agents for SHH MB, and the novel class I HDAC inhibitor JNJ-26481585 (quisinostat) consistently inhibits growth of SHH MB *in vivo* as well as *in vitro* ([@B96]). Another recent study using a high-throughput cell viability assay to screen 12,800 compounds identified two HDACis, JNJ-26481585 and dacinostat, as anti-proliferative agents in MB. Both compounds induce cytotoxicity and apoptosis and block cell cycle progression at the G2/M phase, in addition to reducing the growth of MB xenografts in mice ([@B135]).

Histone deacetylase inhibitors sensitize MB cells to apoptosis induced by cytotoxic chemotherapy via an enhancement of p53-dependent Bax activation ([@B41]). The HDACi sodium butyrate (NaB) at a low dose more effectively inhibits D283 cell viability when combined with the chemotherapeutic etoposide ([@B92]). SAHA combined with 13-cis retinoic acid (RA) induces apoptosis and transcription of bone morphogenetic protein-2 (BMP-2) in MB cells and is more effective than each drug alone in inhibiting MB growth *in vitro* and *in vivo*. Moreover, intracranial MB tumors in mice treated with SAHA plus RA plus cisplatin show a 4-fold increase in apoptosis over controls, and a 2-fold increase over animals receiving only SAHA or RA plus SAHA ([@B115]). The combination of RA with epigenetic modulators in based upon functional interplays among retinoid receptors, histone acetylation, and DNA methylation. For example, HDACs bind to RA response elements in proximal promoters or enhancer regions of genes regulated by retinoids in stem cells, and retinoid receptors interact with the transcription complex mediating the placement or removal of epigenetic marks on histones and DNA ([@B38]; [@B122]; [@B2]). Combinations of HDACis with other epigenetic modulators have also been evaluated. SAHA plus the DNA methyltransferase 1 (DNMT) inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) produce a synergistic effect on survival of Daoy and D283 Med MB cells ([@B133]).

Combining HDACis with growth factor receptor ligands such as receptor tyrosine kinase (RTK) inhibitors (gefitinib or vandetanib) or brain-derived neurotrophic factor (BDNF) is also more effective than each agent given alone in impairing MB cell viability ([@B77]; [@B91]). However, bombesin receptor antagonists failed to potentiate the effects of HDACi inhibition ([@B50]). Other studies have investigated combinations of HDACis with protein kinase signaling inhibitors. The multi-kinase inhibitor sorafenib and VPA interact to radiosensitize and kill MB cell lines ([@B118]). SAHA shows additive cytotoxicity with the Aurora A kinase inhibitor MLN8237 in Daoy cells ([@B87]). A study by [@B33] examined the effects of the pan-aurora kinase inhibitor AMG 900 alone or in combination with SAHA in UW402, UW473, and ONS-76 MB cells. A synergistic effect of combining AMG 900 and SAHA is observed on cell proliferation in all these cell lines, especially in sequential drug treatment. The drug combination also fully inhibits cell survival measured by colony formation. Using an animal model of *MYC*-driven MB to screen for promising drugs, [@B100] found HDACis among the most effective compounds. HDACis potently inhibit survival of *MYC*-driven MB cells, through a mechanism involving expression of the FOXO1 tumor suppressor gene. Importantly, HDACis synergize with phosphatidylinositol 3-kinase (PI3K) inhibitors to inhibit MB growth *in vivo*. NaB reduces viability and increases acetylation in human MB cells, the anti-proliferative effect of NaB being enhanced by combination with a mitogen-activated protein kinase (MAPK)/extracellular-related kinase (ERK) inhibitor ([@B49]).

Ependymoma {#S3.SS2}
----------

Ependymomas featuring a CpG island methylator phenotype respond to drugs that target DNA or H3K27 methylation, revealing epigenetic modulators as the first rational therapeutic candidates in this tumor type ([@B76]). In a high-risk cytogenetic group 3 and molecular group C EPN model (DKFZ-EP1NS) that shows high tumorigenic potential *in vivo*, cells are resistant to cytotoxic chemotherapeutics temozolomide, vincristine, and cisplatin but respond to HDACi treatment ([@B83]).

Diffuse Intrinsic Pontine Glioma {#S3.SS3}
--------------------------------

A seminal study using a chemical screen in patient-derived DIPG cultures along with RNA-seq analyses and integrated computational modeling to identify potentially effective therapeutic strategies has highlighted the potential of HDACs as targets. Importantly, the HDACi panobinostat showed antitumor efficacy both *in vitro* and in orthotopic xenograft models. Furthermore, combination of panobinostat with the histone demethylase inhibitor GSK-J4 showed that the two had synergistic effects ([@B37]). Another study of panobinostat in experimental DIPG found that it effectively impaired cell proliferation, viability, and clonogenicity and induced apoptosis in human and murine DIPG cells. In genetically engineered tumor-bearing mice, panobinostat reduced tumor growth and increased H3 acetylation. Extended daily treatment of both genetic and orthotopic xenograft models with 10 or 20 mg/kg panobinostat led to significant toxicity, while reduced, well-tolerated doses of panobinostat failed to prolong overall survival ([@B45]). In DIPG primary cells, panobinostat potentiated the effects of gene therapy based on human adipose tissue-derived mesenchymal stem cells expressing the secreted form of TRAIL (hAT-MSC.sTRAIL), inducing a decrease in tumor volume and prolonging survival ([@B17]).

Combined treatment with the HDACi panobinostat and the AXL inhibitor BGB324 resulted in synergistic antitumor effects on DIPG cells, with reduced expression of genes related to mesenchymal phenotype, stemness, and DNA damage repair ([@B79]). HDACis also synergize with blockade of bromodomain inhibition or CDK7, which disrupts oncogenic transcription, in DIPG models. HDAC inhibition by panobinostat, together with the bromodomain inhibitor JQ1 or the CDK7 inhibitor THZ1, synergistically reduced cell viability in DIPG cell cultures and proved more effective than single-drug treatments in inhibiting proliferation and inducing apoptosis. Panobinostat and JQ1 induced overlapping transcriptional changes, downregulating many of the same sets of genes ([@B90]). VPA potentiates carboplatin cytotoxicity and increases histone H3 acetylation in different DIPG cell lines ([@B57]). CUDC-907, a first-in-class dual inhibitor of HDACs and PI3K, is a potent cytotoxic agent in DIPG models. Mechanisms underlying CUDC-907 actions include regulation of DNA damage response. It also displays radiosensitizing effects mediated by decreased nuclear factor kappa B (NFκB)/Forkhead box M1 (FOXM1) recruitment to promoters of genes involved in response to DNA damage ([@B97]). A CRISPR screen showed that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to HDACis. Corin, an HDAC and LSD1 inhibitor, hinders *in vitro* and *in vivo* DIPG growth by increasing H3K27me3 levels as well as HDAC-targeted H3K27ac and LSD1-targeted H3K4me1 at differentiation-associated genes ([@B3]).

Rhabdoid and Atypical Teratoid/Rhabdoid Tumors {#S3.SS4}
----------------------------------------------

Atypical teratoid/rhabdoid tumors cell proliferation is impaired by a variety of HDACis, including MS-275, SAHA, TSA, and VPA ([@B48]; [@B30]), and pretreatment with HDACis potentiates the effect of ionizing radiation on ATRT cells as measured by a colony-formation assay ([@B12]; [@B59]). SAHA shows synergism with doxorubicin and the cyclinD1 inhibitor fenretinide in inhibiting proliferation of rhabdoid cells ([@B55]). Objective ATRT tumor regressions accompanied by increases in histone acetylation were observed in mice after treatment with the natural tetrapeptide HDACi depsipeptide ([@B36]). The HDACi FK228 (depsipeptide) induces autophagy in malignant ATRT cells by inducing apoptosis inducing factor (AIF) translocation to the nucleus ([@B128]). The cell cycle inhibitor CDKN1C, a tumor suppressor in ATRT, is activated by HDACis ([@B1]). SAHA combined with fractionated irradiation significantly reduces tumor growth in rhabdoid xenografts ([@B120]). A recent study showed that the epigenetic modulating compound domatinostat (4SC-202), which inhibits both class I HDACs and lysine demethylase (LSD1), displays cytotoxic and cytostatic actions in 2D and 3D ATRT scaffold cell culture models and reduces expression of stemness genes ([@B46]).

The Role of Modulating Stemness and Differentiation {#S4}
===================================================

As discussed above, abnormal epigenetic programming in pediatric cancers may lock tumor cells in a stem cell-like, poorly differentiated state ([@B64]; [@B78]). Pediatric brain tumors often display upregulation of genes known as markers of neural stem cells, including *CD133*, *Nestin*, and *Musashi*, and deregulation of other genes that regulate stemness is frequently found ([@B8]).

HDACis may act partially by restoring expression of prodifferentiation genes, thus influencing tumor cell phenotype toward a less malignant state. In fact, NaB increases the mRNA expression of the neuronal differentiation marker Gria2 in D283 and Daoy cells ([@B92]). The HDACi panobinostat suppresses leptomeningeal seeding (a strong negative prognostic factor) and prolongs survival in an animal model of MB, while also inducing formation of neurophil-like processes and promoting expression of synaptophysin and NeuroD1, suggesting neuronal differentiation ([@B103]). Corin promoted change to a more differentiated phenotype in experimental DIPG ([@B3]). Treatment with low doses of HDACis can induce terminal differentiation of rhabdoid cells and reduce their ability to self-renew ([@B89]).

Given the proposed role of cancer stem cells (CSCs) in the progression, recurrence, and metastasis of brain cancers, studies have also investigated whether HDACis can reduce stemness in MB. Treatment with NaB reduces the formation of MB neurospheres, a model of enriching putative cancer stem cells in culture ([@B92]). Analyses of MB tumor samples from patients reveals expression of the stemness markers *BMI1* and *CD133* in all MB molecular subgroups, and NaB is able to reduce *BMI1* and *CD133* expression in cultured MB cells ([@B49]). In the DKFZ-EP1NS model of EPN, SAHA induces neuronal differentiation associated with loss of stemness ([@B83]). As noted above, HDACi effects in H3K27M DIPG cells involve a decrease in stemness gene expression ([@B79]). These findings support the view that HDACis should be further investigated as prodifferentiating and stemness modulating agents in pediatric brain tumors. A summary of studies examining the effects of pharmacological inhibition of HDACs in the tumor types reviewed here is presented in [Table 1](#T1){ref-type="table"}.

###### 

Research findings from selected experimental studies examining the effects of HDACis in experimental models of pediatric brain tumors.

  **Tumor type**   **Model**                                                                                                                                                                                                                                                                          **HDACis used**                                                                                                                                                                            **Main findings**                                                                                                                                                                                                                                                                                                        **References**
  ---------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      MS-275                                                                                                                                                                                     Reduced cell proliferation                                                                                                                                                                                                                                                                                               [@B48]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      VPA                                                                                                                                                                                        Reduced cell growth and survival, cell cycle arrest; induction of apoptosis, senescence, and neuronal and glial differentiation; hyperacetylation of histones H3 and H4, activation of p21, and suppression of *TP53*, *CDK4*, and *c-MYC*                                                                               [@B69]
  MB               Daoy and D283 Med, subcutaneous (s.c.) xenografts in severe combined immunodeficient mice                                                                                                                                                                                          VPA, daily systemic injections for 28 days                                                                                                                                                 Reduced tumor growth *in vivo*                                                                                                                                                                                                                                                                                           [@B69]
  MB               Daoy and UW228-2, *in vitro*                                                                                                                                                                                                                                                       SAHA, NaB, and TSA                                                                                                                                                                         Impairment of mitochondrial membrane potential, activation of caspase-9, -8, and -3, apoptotic cell death; enhancement of cytotoxicity induced by ionizing radiation (IR), etoposide, and TRAIL                                                                                                                          [@B113], [@B114]
  MB               Daoy and UW228-2, *in vitro*                                                                                                                                                                                                                                                       SAHA and TSA                                                                                                                                                                               Enhancement of IR-induced cytotoxicity and cell cycle arrest                                                                                                                                                                                                                                                             [@B61]
  MB               D458 and primary MB cultures *in vitro*, chorioallantoic membrane model using D458 cells                                                                                                                                                                                           MS-275, VPA, and SAHA                                                                                                                                                                      Cooperation with cytotoxic chemotherapeutics to induce loss of mitochondrial membrane potential, cytochrome c release, and caspase-dependent apoptosis and reduce cell survival and tumor growth                                                                                                                         [@B40]
  MB               D341 Med, Daoy, MHH−PNET−5, and UW228−2, *in vitro*                                                                                                                                                                                                                                MS−275, SAHA, TSA, M344, M360, D85, SW55, SW187, and VPA                                                                                                                                   Reduced cell proliferation, hyperacetylation of H4, reactivation of genes including CASP8; induction of apoptosis                                                                                                                                                                                                        [@B30]
  MB               HD-MB03, *in vitro*                                                                                                                                                                                                                                                                Helminthosporium carbonum (HC)-toxin, SAHA, and panobinostat                                                                                                                               Induction of cell death, sensitization to radiation-induced cell death                                                                                                                                                                                                                                                   [@B84]
  MB               MED8A, UW228-2, ONS76, Daoy, HD-MB03, and D458, *in vitro*                                                                                                                                                                                                                         siRNA-mediated knockdown of HDAC2; HDACis MAZ1863, MAZ1866, SAHA, and MS-275                                                                                                               Reduced metabolic activity, cell number, and viability; increased sensitivity to HDACi in *MYC*-amplified cells; increased H4 acetylation and cell death after HDAC2 knockdown; *in vitro* simulation of clinical pharmacokinetics showed time-dependent on-target activity correlated with binding kinetics of HDACis   [@B22]
  MB               D283 Med, *in vitro*                                                                                                                                                                                                                                                               TSA                                                                                                                                                                                        Upregulation of Dickkopf-1 (DKK1), a Wnt antagonist                                                                                                                                                                                                                                                                      [@B123]
  MB               ONS-76, *in vitro*                                                                                                                                                                                                                                                                 TSA                                                                                                                                                                                        Inhibition of telomerase activity, increased expression of p53 and p21, and reduced cyclin-D levels; upregulation of Bax and cytochrome c correlates with TSA-induced apoptosis                                                                                                                                          [@B56]
  MB               HEK293T, *in vitro*                                                                                                                                                                                                                                                                TSA, NaB, and VPA                                                                                                                                                                          Inhibition of ZNF521 cooperation with GLI1 and GLI2 in the transcriptional activation of GLI-responsive promoters                                                                                                                                                                                                        [@B109]
  MB               Primary culture of CGP cells from Smo/Smo mice, *in vitro*                                                                                                                                                                                                                         TSA and tubastatin                                                                                                                                                                         Impairment of Shh-induced CGP proliferation and improvement of aberrant CGP proliferation                                                                                                                                                                                                                                [@B66]
  MB               NIH3T3−12Gli, *in vitro*                                                                                                                                                                                                                                                           NL-103, SAHA                                                                                                                                                                               Decreased resistance to vismodegib, inhibition of the Shh pathway                                                                                                                                                                                                                                                        [@B136]
  MB               NIH3T3, Hek293A, ShhL2, and C3H10T1/2, *in vitro*                                                                                                                                                                                                                                  TSA, ACY-1215, CAY-10603, tubacin                                                                                                                                                          Inhibition of Hh signaling and expression of genes encoding for components of the Hh pathway                                                                                                                                                                                                                             [@B19]
  MB               S.c. injection of primary MB99-1 cells from SmoA1 MB E1270) into C57BL/6J mice                                                                                                                                                                                                     S.c. administration of ACY-1215 (50 mg/kg on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11 after tumors were palpable                                                                            Reduced tumor growth                                                                                                                                                                                                                                                                                                     [@B19]
  MB               Cre-dependent *in vitro* system for SHH-driven MB based on cultured primary cerebellar granule neuron precursors from *SmoM2*^Fl/+^ and *Crebbp^Fl/F^lSm oM2^Fl/+^* mice                                                                                                           TSA                                                                                                                                                                                        Preferential reduction in cell proliferation and tumor growth in SHH-driven MB harboring a CREBBP mutation                                                                                                                                                                                                               [@B44]
  MB               *Math1-creER^T2^::SmoM2^Fl/+^* mice with CREBBP-mutated SHH MB                                                                                                                                                                                                                     Intraperitoneal (i.p.) administration of TSA (0.5 μg/g, once daily) or LBH-589 (panobinostat, 20 μg/g, once weekly) for 30 days                                                            Preferential reduction of tumor growth in SHH-driven MB harboring a CREBBP-mutation                                                                                                                                                                                                                                      [@B44]
  MB               SMB21 (SHH-dependent murine MB cell line) and its mutant derivatives, *in vitro*                                                                                                                                                                                                   JNJ-26481585 (quisinostat), DLS-3, MERCK 60, WT 161, OJI-1, and pandacostat                                                                                                                Inhibitor-specific reduction of cell viability, including SMO-resistant SHH cells, and inhibition of the SHH pathway                                                                                                                                                                                                     [@B96]
  MB               S.c. xenografts into the flank of nude mice; and endogenously arising intracranial SHH MB model in *Atoh1-cre::SmoM2^Fl/+^* mice                                                                                                                                                   Systemic administration of JNJ-26481585 (8 mg/kg) daily, starting at postnatal day P20                                                                                                     Survival benefit, reduction in expression of SHH target genes *Gli1* and *Ptch1*, good pharmacokinetic profile                                                                                                                                                                                                           [@B96]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      JNJ-26481585 or dacinostat                                                                                                                                                                 Reduced cell viability, apoptosis, and Akt phosphorylation; G2/M cell cycle arrest; increased histone H3 and H4 acetylation                                                                                                                                                                                              [@B135]
  MB               S.c. Daoy xenografts in the flank of NSG mice                                                                                                                                                                                                                                      I.p. administration of JNJ-26481585 or dacinostat (20 mg/kg) every 2 days starting when tumor volumes reached 100 mm^3^                                                                    Inhibition of tumor growth and cell proliferation and increased apoptosis                                                                                                                                                                                                                                                [@B135]
  MB               D458 and primary cultures, *in vitro*                                                                                                                                                                                                                                              MS-275, VPA, SAHA                                                                                                                                                                          Increased histone H3 and Ku70 acetylation; MS-275 pretreatment-induced enhancement of apoptosis triggered by doxorubicin, etoposide, cisplatin, and topotecan                                                                                                                                                            [@B41]
  MB               Chorioallantoic membrane model using D458 cells                                                                                                                                                                                                                                    MS-275                                                                                                                                                                                     Increased efficacy in inhibiting tumor growth when combined with doxorubicin                                                                                                                                                                                                                                             [@B41]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      NaB                                                                                                                                                                                        Increased cell death and expression of the neuronal marker Gria2; reduced neurosphere formation; potentiation of cytotoxic effect of etoposide                                                                                                                                                                           [@B92]
  MB               D283 Med, *in vitro*                                                                                                                                                                                                                                                               SAHA                                                                                                                                                                                       Enhancement of RA-mediated BMP-2 transcription; induction of apoptosis-mediated cell death potentiated by combination with RA                                                                                                                                                                                            [@B115]
  MB               s.c. D283 xenografts injected into the flank of nude mice; intracranial MB in ND2:SmoA1 transgenic mice                                                                                                                                                                            SAHA mixed into powdered food at a final concentration of 200 mg/kg/day for up to 21 days (nude mice); i.p. injections of SAHA (200 mg/kg) daily for 3 days in ND2:SmoA1 transgenic mice   Reduced tumor growth with oral SAHA combined with RA in nude mice; increased apoptosis in intracranial tumors and lack of dose-limiting hematopoietic toxicity in ND2:SmoA1 mice                                                                                                                                         [@B115]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      TSA, SAHA, parthenolide, mocetinostat, tacedinaline, romidepsin                                                                                                                            Reduced oxygen-dependent cell viability, induction of apoptosis, reduced expression of the stem cell marker CD133, reduced tumorsphere survival. Increased cytotoxic and proapoptotic effects when combined with the DNMT inhibitor 5-aza-dC                                                                             [@B133]
  MB               Daoy, *in vitro*                                                                                                                                                                                                                                                                   4-Phenylbutyrate                                                                                                                                                                           Reduced cell viability only when combined with gefitinib; potentiation of effects of gefitinib and vandetanib on cell survival                                                                                                                                                                                           [@B77]
  MB               Daoy and ONS76, *in vitro*                                                                                                                                                                                                                                                         NaB                                                                                                                                                                                        Reduction in cell viability by HDACis combined with human recombinant BDNF                                                                                                                                                                                                                                               [@B91]
  MB               D283 Med, *in vitro*                                                                                                                                                                                                                                                               NaB                                                                                                                                                                                        Reduction of cell viability by NaB alone or combined with bombesin receptor antagonists                                                                                                                                                                                                                                  [@B50]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      VPA, SAHA                                                                                                                                                                                  Induction of cell death through activation of the extrinsic pathway when combined with sorafenib                                                                                                                                                                                                                         [@B118]
  MB               Daoy, *in vitro*                                                                                                                                                                                                                                                                   SAHA                                                                                                                                                                                       Increased histone acetylation, induction of cytotoxicity, synergistic effects when combined with MLN8237                                                                                                                                                                                                                 [@B87]
  MB               UW402, UW473, and ONS-76, *in vitro*                                                                                                                                                                                                                                               SAHA                                                                                                                                                                                       Reduced cell proliferation and survival alone or combined with AMG 900                                                                                                                                                                                                                                                   [@B33]
  MB               Patient-derived lines including MB002, ICb-984, ICb-1572, ICb-1487, ICb-1299, Med-1712-FH, Med-411-FH, Med-211-FH, RCMB28, RCMB18, RCMB32, DMB006                                                                                                                                  SAHA, HNHA, LBH-589, Scriptaid, MS-275, givinostat, PDX 101, LAQ-824, and MGCD0103                                                                                                         Inhibition of cell survival through a mechanism targeting FOXO1; synergistic effect with PI3K inhibitors                                                                                                                                                                                                                 [@B100]
  MB               *In vivo* intracranial tumors generated in NOD-SCID IL2R-gamma null (NSG) mice, from cerebellar stem/progenitor cells (Prom1+ cells) infected with Myc-IRES-Luciferase and DNp53-IRES-GFP retroviruses and stereotaxically injected into the cerebellum of 6- to 8-week-old mice   LBH-589 (5 mg/kg) given i.p., in 4-day cycles (3 days on, 1 day off)                                                                                                                       Reduced phosphorylation of Akt and S6, increased histone acetylation and FOXO1 content, reduced tumor growth, and prolonged survival; cooperation with the PI3K inhibitor BKM-120                                                                                                                                        [@B100]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      NaB                                                                                                                                                                                        Reductions in cell viability and expression of *BMI1* and *CD133*; increased acetylation; anti-proliferative effect potentiated by combination with the MAPK/ERK inhibitor U0126                                                                                                                                         [@B49]
  MB               UW228, UW426, MED8A, *in vitro*                                                                                                                                                                                                                                                    Panobinostat                                                                                                                                                                               Reduced cell viability, migration, and adhesion, cell cycle arrest, induction of apoptosis, and neuronal differentiation                                                                                                                                                                                                 [@B103]
  MB               Orthotopic injection of UW426-effLuc cells in nude mice                                                                                                                                                                                                                            Systemic administration of panobinostat (10 mg/kg) every 5 days for 2 weeks                                                                                                                Reduction of tumor growth and leptomeningeal seeding, prolonged survival                                                                                                                                                                                                                                                 [@B103]
  MB               Daoy and D283 Med, *in vitro*                                                                                                                                                                                                                                                      FTY720                                                                                                                                                                                     Reduced cell viability and survival, increased H3 acetylation                                                                                                                                                                                                                                                            [@B101]
  EPN              DKFZ-EP1NS, *in vitro*                                                                                                                                                                                                                                                             SAHA, panobinostat, MS-275, and VPA                                                                                                                                                        Reduced metabolic activity and neurosphere formation capability; induction of neuronal differentiation; loss of stemness; G0--G1 cell cycle arrest                                                                                                                                                                       [@B83]
  DIPG             SU, NEM, JHH. Li, VU, JHH-DIPG-1, SF7761, and primary cultures, *in vitro*                                                                                                                                                                                                         Panobinostat and SAHA                                                                                                                                                                      Decreased cell viability, increased H3 acetylation and H3K27-trimethylation, normalization of K27M gene expression signature, and decrease in *MYC* gene signature; synergism with GSK-J4                                                                                                                                [@B37]
  DIPG             DIPG orthotopic xenograft mouse model, using cells from SU-DIPG-VI-luc neurospheres and NOD-SCID-IL2 gamma chain-deficient mice                                                                                                                                                    Pabinostat infused into the pons or given via i.p. injections                                                                                                                              Prolonged survival                                                                                                                                                                                                                                                                                                       [@B37]
  DIPG             HSJD-DIPG-007                                                                                                                                                                                                                                                                      Panobinostat                                                                                                                                                                               Reduced cell survival                                                                                                                                                                                                                                                                                                    [@B45]
  DIPG             Autochthonous PDGF-B;H3.3-K27M;p53-deficient BSG genetically engineered mice and DIPG orthotopic xenograft mouse model                                                                                                                                                             i.p. administration of panobinostat (10 to 20 mg/kg), once daily for three to five days                                                                                                    Drug delivery to the brain after systemic administration, reduced tumor cell proliferation, increased H3 acetylation                                                                                                                                                                                                     [@B45]
  DIPG             DIPG XIII: H3.3 K27M and DIPG XIX: H3.3 K27M primary cells; *in vitro*                                                                                                                                                                                                             Panobinostat                                                                                                                                                                               Reduced cell viability; increased expression of death receptors 4 and 5; cytotoxicity potentiated by combination with hAT-MSC.sTRAIL                                                                                                                                                                                     [@B17]
  DIPG             VUMC-DIPG-A, VUMC-DIPG-08, VUMC-DIPG-10, SU-DIPG-IV, SU-DIPG-XIII, SU-DIPG-XXI, SU-pcGBM-2, HSJD-DIPG-07, HSJD-DIPG-08, HSJD-DIPG-12, JHH DIPG-01, SF7761, SF862826, and mouse cell lines from murine primary tumors, *in vitro*                                                   Panobinostat                                                                                                                                                                               Reduced cell viability and migration; reversal of mesenchymal transition; sensitization to radiation; synergism with the AXL inhibitor BGB324                                                                                                                                                                            [@B79]
  DIPG             Orthotopic xenografts of HSJD-DIPG-07 Fluc cells in nude mice                                                                                                                                                                                                                      Panobinostat (10 mg/kg/day) for four days, or on days 1--5 and 11--13; or a single administration via convection-enhanced delivery (CED, 2 μM)                                             Prolonged survival when combined with BGB324                                                                                                                                                                                                                                                                             [@B79]
  DIPG             SU-DIPG-IV: H3.1-K27M, SU-DIPG-VI/XIII-P, SU-DIPG-XVII, SU-DIPG-XXV JHH-DIPG1, SF7761: H3.3-K27M, SU-DIPG-XIII-FL, and VUMC-DIPG-10, *in vitro*                                                                                                                                    Panobinostat                                                                                                                                                                               Synergistic effects with the bromodomain inhibitor JQ1 and the CDK7 inhibitor THZ1 in reducing cell viability and proliferation and inducing apoptosis; changes in expression of genes related to central nervous system development and synaptic organization and structure                                             [@B90]
  DIPG             SF7761, SF8628, and DUB-D003, *in vitro*                                                                                                                                                                                                                                           VPA                                                                                                                                                                                        Reduced cell survival, increased histone H3 acetylation and apoptosis, potentiation of carboplatin cytotoxicity                                                                                                                                                                                                          [@B57]
  DIPG             BT869, SF8628, and SF10693                                                                                                                                                                                                                                                         CUDC-907                                                                                                                                                                                   Cytotoxicity with synergism with radiotherapy for CUDC-907; cell cycle arrest, increased DNA damage and reduced DNA repair; inhibition of NFκB and FOXM1 expression and transcriptional activity                                                                                                                         [@B97]
  DIPG             Orthotopic injection of SF8628 cells in nude mice                                                                                                                                                                                                                                  CUDC-907 (100 mg/kg), orally for 10 days                                                                                                                                                   Increased survival with CUDC-907, with potentiation when combined with radiotherapy                                                                                                                                                                                                                                      [@B97]
  DIPG             SU-DIPGVI, SU-DIPGXIII, BT869, BT245, and HSJD-DIPG007                                                                                                                                                                                                                             Panobinostat, entinostat, and Corin                                                                                                                                                        Reduced cell viability, global changes in histone and chromatin modifications and gene expression, cell cycle arrest, induction of differentiation                                                                                                                                                                       [@B3]
  DIPG             HSJD-DIPG007 and SU-DIPGXIIIP\* orthotopic xenografts in nude mice                                                                                                                                                                                                                 Corin (0.03 mg) given via CED                                                                                                                                                              Reduced tumor growth, increased H3K27ac and H3K27me3                                                                                                                                                                                                                                                                     [@B3]
  ATRT             G401, *in vitro*                                                                                                                                                                                                                                                                   MS-275                                                                                                                                                                                     Reduced DNA synthesis and viability, increase in G1, induction of p21                                                                                                                                                                                                                                                    [@B48]
  ATRT             BT 12, BT 16, 7.92, and G401, *in vitro*                                                                                                                                                                                                                                           MS-275, SAHA, TSA, VPA, M344, M360, D85, SW55, SW187                                                                                                                                       Reduced cell viability, increased H3 and H4 acetylation, apoptosis induction                                                                                                                                                                                                                                             [@B30]
  ATRT             KHOS-2405 and A-204, *in vitro*                                                                                                                                                                                                                                                    SAHA                                                                                                                                                                                       Reduced cell viability, increased γH2AX expression                                                                                                                                                                                                                                                                       [@B12]
  ATRT             BT-12, BT-16, and UPN737                                                                                                                                                                                                                                                           SAHA, TSA, and SNDX-275                                                                                                                                                                    Reduced proliferation, increased p21^Waf1/Cip1^ content, induction of apoptosis, potentiation of radiation-induced inhibitor effects on cell survival                                                                                                                                                                    [@B59]
  ATRT             BT-12, BT-16, G401, and A-204                                                                                                                                                                                                                                                      SAHA, TSA, and M344                                                                                                                                                                        Induction of apoptosis, G2 arrest, expression of RB-, MYC-, and pluripotency-associated genes, synergistic cell growth inhibition and apoptosis induction when combined with fenretinide or chemotherapy                                                                                                                 [@B55]
  ATRT             S.c xenografts of primary tumors in *scid* mice                                                                                                                                                                                                                                    Depsipeptide (4.4 mg/kg) given intravenously (i.v.) every 7 days × 3 with a second cycle of treatment starting on day 21                                                                   Reduced tumor growth, increased histone acetylation, p21 and p53 induction, cleavage of PARP                                                                                                                                                                                                                             [@B36]
  ATRT             G401, STM91-01, SJSC, and BT-16                                                                                                                                                                                                                                                    Romidepsin                                                                                                                                                                                 Increased CDKN1C mRNA expression and histone acetylation at the CDKN1C promoter, changes in allelic expression of *CDKN1C*                                                                                                                                                                                               [@B1]
  ATRT             A-204 s.c. xenografts in nude mice                                                                                                                                                                                                                                                 SAHA (100 mg/kg) injected i.p. once daily for 8 consecutive days or for 15 days within three weeks                                                                                         Reduced tumor growth with reduced cell proliferation and increased apoptosis with drug treatment alone or combined with radiotherapy                                                                                                                                                                                     [@B120]
  ATRT             CHLA-06-ATRT and CHLA-05-ATRT, *in vitro* and spheroid and 3D Scaffold models                                                                                                                                                                                                      4SC-202                                                                                                                                                                                    Cytotoxicity, reduced stem cell marker expression, changes in gene networks                                                                                                                                                                                                                                              [@B46]
  ATRT             G401, SJSC, STM91-01 *in vitro*                                                                                                                                                                                                                                                    LBH589                                                                                                                                                                                     Reduced cell viability and self-renewal, induction of senescence, increased H3 and H4 acetylation                                                                                                                                                                                                                        [@B89]
  ATRT             S.c. xenografts of G401 or SJSC in nude mice                                                                                                                                                                                                                                       Daily i.p. injections of LBH589 (5 mg/kg)                                                                                                                                                  Reduced tumor growth, increased differentiation                                                                                                                                                                                                                                                                          [@B89]

See main text for abbreviation definitions and further details.

Clinical Trials of HDACis in Pediatric Brain Tumors {#S5}
===================================================

A phase-I/II dose-escalation clinical trial of SAHA in pediatric patients with recurrent solid tumors including brain tumors has been reported ([@B129]). Another phase I trial and pharmacokinetic study of SAHA in children with solid tumors indicated that SAHA was well-tolerated at a dose of 230 mg/m(2)/d, with a small dose reduction required when SAHA was combined with RA ([@B26]). Another phase-I consortium clinical study recommended a dose and schedule of vorinostat at 230 mg/m(2)/day PO on days 1--5 and 8--12 in combination with the proteasome inhibitor bortezomib at 1.3 mg/m(2)/day i.v. on days 1, 4, 8, and 11 of a 21-day cycle, for future phase 2 studies in children with recurrent or refractory solid tumors ([@B88]). SAHA and a range of other epigenetic therapies have been evaluated in clinical trials of patients with DIPG ([@B42]). An ongoing multicenter, multiarm phase II and III trial investigates the effects of conventional chemotherapy with or without combination with an HDACi in patients with EPN ([@B81]).

Conclusion {#S6}
==========

Some HDACis have already been approved by the United States Food and Drug Administration (FDA) for the treatment of other cancer types (i.e., SAHA and romidepsin for the treatment of cutaneous T-cell lymphoma and belinostat and panobinostat for the treatment of peripheral T-cell lymphoma and multiple myeloma, respectively). Given the increasingly promising role of drug repurposing or repositioning in the identification of potential novel therapeutic strategies for pediatric brain tumors ([@B7]), those agents could be tested in clinical trials of patients with these cancer types. VPA is well tolerated in patients with childhood brain cancers, including heavily pretreated pediatric patients with HGG or DIPG ([@B130]; [@B129]), and could also be evaluated for efficacy in clinical trials of pediatric brain tumors. Moreover, fingolimod (FTY720), an immunosuppressant agent currently used clinically in the treatment of multiple sclerosis, displays HDAC-inhibiting properties and has been recently shown to reduce the growth of experimental MB ([@B32]; [@B101]). Reduced D283 and Daoy cell viability by fingolimod was accompanied by increases in acetylated histone H3 levels, highlighting a role for histone acetylation ([@B101]). Thus, fingolimod is a new candidate drug for clinical testing in patients with MB. One potential limitation for the clinical use of some HDACis such as panobinostat for brain tumors is poor permeability across the blood--brain barrier (BBB) after oral administration ([@B106]). Novel formulations and drug administration techniques such as convection-enhanced delivery (CED) are emerging strategies to bypass the BBB, one example being MTC110, a water-soluble formulation of panobinostat ([@B112]). Pharmacogenomic differences among individual patients pose another challenge for the clinical use of HDACis. Polymorphic enzymes and drug transporters are involved in metabolizing and transporting HDACis, making genotype-specific dose a strategy to reduce the risk of toxicity and avoid suboptimal treatment ([@B35]). Taken together, the evidence reviewed here strongly provides support for further clinical testing of HDACis as part of the pharmacological treatment available to pediatric brain cancer patients, particularly those with MB or DIPG, tumor types for which there is a larger body of experimental evidence. As the field of therapeutic use of HDACis for the treatment of brain cancer evolves, one can expect the development and testing of more selective HDACis that will target specific HDACs and alter the acetylation status of a relatively small number of substrates, potentially reducing side effects associated with less selective HDACis.
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